DOXIMITY INC-CLASS A (DOCS) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:DOCS - US26622P1075 - Common Stock
50.42 USD
+4 (+8.62%)
50.6 USD
+0.18 (+0.36%)
Taking everything into account, DOCS scores 7 out of 10 in our fundamental rating. DOCS was compared to 35 industry peers in the Health Care Technology industry. DOCS gets an excellent profitability rating and is at the same time showing great financial health properties. DOCS is not overvalued while it is showing excellent growth. This is an interesting combination. These ratings would make DOCS suitable for growth and quality investing!
1. Profitability
1.1 Basic Checks
In the past year DOCS was profitable.
DOCS had a positive operating cash flow in the past year.
In the past 5 years DOCS has always been profitable.
DOCS had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
DOCS's Return On Assets of 20.13% is amongst the best of the industry. DOCS outperforms 100.00% of its industry peers.
The Return On Equity of DOCS (23.10%) is better than 100.00% of its industry peers.
DOCS has a better Return On Invested Capital (18.16%) than 100.00% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for DOCS is significantly above the industry average of 6.84%.
The 3 year average ROIC (14.17%) for DOCS is below the current ROIC(18.16%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.13% | ||
| ROE | 23.1% | ||
| ROIC | 18.16% |
ROA(3y)13.75%
ROA(5y)12.65%
ROE(3y)16.22%
ROE(5y)15.68%
ROIC(3y)14.17%
ROIC(5y)16.48%
1.3 Margins
With an excellent Profit Margin value of 40.72%, DOCS belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
In the last couple of years the Profit Margin of DOCS has grown nicely.
The Operating Margin of DOCS (39.72%) is better than 100.00% of its industry peers.
DOCS's Operating Margin has improved in the last couple of years.
The Gross Margin of DOCS (90.20%) is better than 97.14% of its industry peers.
DOCS's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 39.72% | ||
| PM (TTM) | 40.72% | ||
| GM | 90.2% |
OM growth 3Y6.88%
OM growth 5Y16.16%
PM growth 3Y0.28%
PM growth 5Y33.35%
GM growth 3Y0.66%
GM growth 5Y0.68%
2. Health
2.1 Basic Checks
DOCS has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
DOCS has more shares outstanding than it did 1 year ago.
DOCS has more shares outstanding than it did 5 years ago.
DOCS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 37.29 indicates that DOCS is not in any danger for bankruptcy at the moment.
DOCS's Altman-Z score of 37.29 is amongst the best of the industry. DOCS outperforms 100.00% of its industry peers.
DOCS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 37.29 |
ROIC/WACC1.7
WACC10.66%
2.3 Liquidity
A Current Ratio of 7.79 indicates that DOCS has no problem at all paying its short term obligations.
The Current ratio of DOCS (7.79) is better than 94.29% of its industry peers.
A Quick Ratio of 7.79 indicates that DOCS has no problem at all paying its short term obligations.
The Quick ratio of DOCS (7.79) is better than 94.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.79 | ||
| Quick Ratio | 7.79 |
3. Growth
3.1 Past
DOCS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 46.43%, which is quite impressive.
Measured over the past years, DOCS shows a very strong growth in Earnings Per Share. The EPS has been growing by 79.21% on average per year.
The Revenue has grown by 20.21% in the past year. This is a very strong growth!
Measured over the past years, DOCS shows a very strong growth in Revenue. The Revenue has been growing by 37.42% on average per year.
EPS 1Y (TTM)46.43%
EPS 3Y20.79%
EPS 5Y79.21%
EPS Q2Q%50%
Revenue 1Y (TTM)20.21%
Revenue growth 3Y18.42%
Revenue growth 5Y37.42%
Sales Q2Q%23.16%
3.2 Future
DOCS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.47% yearly.
DOCS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.87% yearly.
EPS Next Y9.97%
EPS Next 2Y10.23%
EPS Next 3Y11.25%
EPS Next 5Y13.47%
Revenue Next Year12.23%
Revenue Next 2Y11.74%
Revenue Next 3Y11.52%
Revenue Next 5Y11.87%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 30.74, DOCS can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Earnings ratio of DOCS indicates a somewhat cheap valuation: DOCS is cheaper than 77.14% of the companies listed in the same industry.
DOCS is valuated rather expensively when we compare the Price/Earnings ratio to 25.45, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 29.43, the valuation of DOCS can be described as expensive.
65.71% of the companies in the same industry are more expensive than DOCS, based on the Price/Forward Earnings ratio.
DOCS's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 34.46.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 30.74 | ||
| Fwd PE | 29.43 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of DOCS indicates a somewhat cheap valuation: DOCS is cheaper than 62.86% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, DOCS is valued a bit cheaper than the industry average as 65.71% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 30.26 | ||
| EV/EBITDA | 30.39 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
DOCS has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)3.08
PEG (5Y)0.39
EPS Next 2Y10.23%
EPS Next 3Y11.25%
5. Dividend
5.1 Amount
DOCS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
50.42
+4 (+8.62%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners90.54%
Inst Owner Change-0.01%
Ins Owners1.94%
Ins Owner Change0.19%
Market Cap9.44B
Revenue(TTM)621.33M
Net Income(TTM)253.03M
Analysts76.92
Price Target71.12 (41.06%)
Short Float %3.15%
Short Ratio2.63
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.98%
Min EPS beat(2)16.41%
Max EPS beat(2)17.55%
EPS beat(4)4
Avg EPS beat(4)25.31%
Min EPS beat(4)16.41%
Max EPS beat(4)36.67%
EPS beat(8)8
Avg EPS beat(8)23.42%
EPS beat(12)12
Avg EPS beat(12)22.47%
EPS beat(16)16
Avg EPS beat(16)28.98%
Revenue beat(2)2
Avg Revenue beat(2)3.67%
Min Revenue beat(2)2.52%
Max Revenue beat(2)4.82%
Revenue beat(4)4
Avg Revenue beat(4)4.22%
Min Revenue beat(4)1.38%
Max Revenue beat(4)8.16%
Revenue beat(8)7
Avg Revenue beat(8)3.68%
Revenue beat(12)9
Avg Revenue beat(12)2.53%
Revenue beat(16)12
Avg Revenue beat(16)2.69%
PT rev (1m)0.24%
PT rev (3m)2.03%
EPS NQ rev (1m)-0.03%
EPS NQ rev (3m)0%
EPS NY rev (1m)0.27%
EPS NY rev (3m)0.04%
Revenue NQ rev (1m)1.18%
Revenue NQ rev (3m)0.87%
Revenue NY rev (1m)0.24%
Revenue NY rev (3m)0.18%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 30.74 | ||
| Fwd PE | 29.43 | ||
| P/S | 15.2 | ||
| P/FCF | 30.26 | ||
| P/OCF | 29.54 | ||
| P/B | 8.62 | ||
| P/tB | 9.72 | ||
| EV/EBITDA | 30.39 |
EPS(TTM)1.64
EY3.25%
EPS(NY)1.71
Fwd EY3.4%
FCF(TTM)1.67
FCFY3.3%
OCF(TTM)1.71
OCFY3.39%
SpS3.32
BVpS5.85
TBVpS5.19
PEG (NY)3.08
PEG (5Y)0.39
Graham Number14.69
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.13% | ||
| ROE | 23.1% | ||
| ROCE | 22.1% | ||
| ROIC | 18.16% | ||
| ROICexc | 85.05% | ||
| ROICexgc | 177.37% | ||
| OM | 39.72% | ||
| PM (TTM) | 40.72% | ||
| GM | 90.2% | ||
| FCFM | 50.23% |
ROA(3y)13.75%
ROA(5y)12.65%
ROE(3y)16.22%
ROE(5y)15.68%
ROIC(3y)14.17%
ROIC(5y)16.48%
ROICexc(3y)82.49%
ROICexc(5y)193.92%
ROICexgc(3y)186.25%
ROICexgc(5y)N/A
ROCE(3y)17.25%
ROCE(5y)20.05%
ROICexgc growth 3Y3.35%
ROICexgc growth 5YN/A
ROICexc growth 3Y-4.75%
ROICexc growth 5YN/A
OM growth 3Y6.88%
OM growth 5Y16.16%
PM growth 3Y0.28%
PM growth 5Y33.35%
GM growth 3Y0.66%
GM growth 5Y0.68%
F-Score9
Asset Turnover0.49
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 64.81% | ||
| Cap/Sales | 1.23% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 123.66% | ||
| Profit Quality | 123.35% | ||
| Current Ratio | 7.79 | ||
| Quick Ratio | 7.79 | ||
| Altman-Z | 37.29 |
F-Score9
WACC10.66%
ROIC/WACC1.7
Cap/Depr(3y)59.31%
Cap/Depr(5y)83.25%
Cap/Sales(3y)1.28%
Cap/Sales(5y)1.55%
Profit Quality(3y)131.35%
Profit Quality(5y)169.54%
High Growth Momentum
Growth
EPS 1Y (TTM)46.43%
EPS 3Y20.79%
EPS 5Y79.21%
EPS Q2Q%50%
EPS Next Y9.97%
EPS Next 2Y10.23%
EPS Next 3Y11.25%
EPS Next 5Y13.47%
Revenue 1Y (TTM)20.21%
Revenue growth 3Y18.42%
Revenue growth 5Y37.42%
Sales Q2Q%23.16%
Revenue Next Year12.23%
Revenue Next 2Y11.74%
Revenue Next 3Y11.52%
Revenue Next 5Y11.87%
EBIT growth 1Y22.24%
EBIT growth 3Y26.56%
EBIT growth 5Y59.63%
EBIT Next Year15.19%
EBIT Next 3Y13.45%
EBIT Next 5Y12.98%
FCF growth 1Y94.7%
FCF growth 3Y30.18%
FCF growth 5Y64.72%
OCF growth 1Y93.3%
OCF growth 3Y29.24%
OCF growth 5Y59.83%
DOXIMITY INC-CLASS A / DOCS FAQ
What is the fundamental rating for DOCS stock?
ChartMill assigns a fundamental rating of 7 / 10 to DOCS.
Can you provide the valuation status for DOXIMITY INC-CLASS A?
ChartMill assigns a valuation rating of 4 / 10 to DOXIMITY INC-CLASS A (DOCS). This can be considered as Fairly Valued.
How profitable is DOXIMITY INC-CLASS A (DOCS) stock?
DOXIMITY INC-CLASS A (DOCS) has a profitability rating of 9 / 10.
What is the earnings growth outlook for DOXIMITY INC-CLASS A?
The Earnings per Share (EPS) of DOXIMITY INC-CLASS A (DOCS) is expected to grow by 9.97% in the next year.